Structure Therapeutics Inc. American Depositary Shares (NASDAQ:GPCR)

Home >> Stock >> Structure Therapeutics Inc. American Depositary Shares >> Ratio

Blog+More

We assess how stablecoins and blockchains can combine to strengthen the U.S. Treasury bond market after the recent U.S. congressional passage of the GENIUS Act.

John Fourier

2027-07-31 13:25:00 Saturday ET

We assess how stablecoins and blockchains can combine to strengthen the U.S. Treasury bond market after the recent U.S. congressional passage of the GENIUS Act.

In the broader context of stablecoins for asset tokenization worldwide, many governments now seek to enter the global markets for stablecoins and other U.S.

+See More

Apple upstream semiconductor chipmaker TSMC boosts capital expenditures to $15 billion with almost 10% revenue growth by December 2019.

John Fourier

2019-11-11 09:36:00 Monday ET

Apple upstream semiconductor chipmaker TSMC boosts capital expenditures to $15 billion with almost 10% revenue growth by December 2019.

Apple upstream semiconductor chipmaker TSMC boosts capital expenditures to $15 billion with almost 10% revenue growth by December 2019. Due to high global d

+See More

CEO overconfidence and corporate performance

Laura Hermes

2022-11-05 11:32:00 Saturday ET

CEO overconfidence and corporate performance

CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers an

+See More

What are the mainstream technological advances in the global auto industry?

Chanel Holden

2024-04-30 09:30:00 Tuesday ET

What are the mainstream technological advances in the global auto industry?

With clean and green energy resources and electric vehicles, the global auto industry now navigates at a newer and faster pace. Both BYD and Tesla have

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Ramit Sethi suggests that it is important to invest in long-term gains instead of paying attention to daily dips and trends.

John Fourier

2018-10-30 10:41:00 Tuesday ET

Ramit Sethi suggests that it is important to invest in long-term gains instead of paying attention to daily dips and trends.

Personal finance author Ramit Sethi suggests that it is important to invest in long-term gains instead of paying attention to daily dips and trends. It

+See More